Abstract: Objective The objective of this study was to investigate the clinical efficacy and safety of intravenous continuous pumping and infusion of Endostar combined with platinum-containing dual-drug regimen as first-line chemotherapy in the treatment of advanced non-small cell lung cancer(NSCLC).Methods A total of 100 advanced NSCLC patients with pathological classification of adenocarcinoma who were admitted to Renmin Hospital of Wuhan University from December 2011 to December 2020 were selected as the research objects.The observation group was the CIV group,a total of 50 patients in the group were treated with Endostar intravenous continuous pumping combined with pemetrexed and nedaplatin.The control group was the DIV group,with the other 50 patients treated with Endostar intravenous infusion combined with pemetrexed and nedaplatin chemotherapy regimen.The overall response rate(ORR),disease control rate(DCR),and the occurrence of toxic and side effects between the two groups of patients were compared.Results The ORR of the observation group was 38.0%,which was higher than that of the control group(18.0%).The difference was statistically significant(P=0.026).The DCR of the observation group was 92.0%,which was higher than that of the control group(74.0%),and the difference was statistically significant(P=0.017).The occurrence of toxic and side effects was not statistically significant(P＞0.05).The results of Cox regression analysis showed that the method of administration was not a factor influencing progression-free survival(PFS)in patients with advanced NSCLC(P=0.340),and radiotherapy was an independent factor affecting PFS in patients with advanced NSCLC(P＜0.05).The PFS of patients who received radiotherapy was longer than that of patients who did not receive radiotherapy(HR=1.708,95% CI:1.041~2.801).Conclusion The ORR and DCR of patients with advanced NSCLC treated with continuous intravenous pumping combined with first-line chemotherapy with platinum-containing two-drug regimen were higher than those treated with intravenous infusion,without aggravating related toxic and side effects.Among them,the risk of tumor progression in patients receiving radiotherapy was lower than that in patients not receiving radiotherapy.

Key words: Non-small cell lung cancer, Endostar, Continuous intravenous pumping, Intravenous infusion, Platinum-containing dual-drug chemotherapy